Design and synthesis of Rho kinase inhibitors (II)

被引:42
作者
Iwakubo, Masayuki [1 ]
Takami, Atsuya [1 ]
Okada, Yuji [1 ]
Kawata, Takehisa [1 ]
Tagami, Yoshimichi [1 ]
Ohashi, Hiroshi [1 ]
Sato, Motoko [1 ]
Sugiyama, Terumi [1 ]
Fukushima, Kayoko [1 ]
Iijima, Hiroshi [1 ]
机构
[1] Kirin Brewery Co Ltd, Pharmaceut Res Labs, Takasaki, Gunma 3701295, Japan
关键词
Rho kinase; inhibitor; CCR2; MCP-1; structure-activity relationship;
D O I
10.1016/j.bmc.2006.09.052
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In a previous study, we identified several structurally unrelated scaffolds of the Rho kinase inhibitor using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. 1H-Indazole is one of the candidate scaffolds on which a new series of potent Rho kinase inhibitors could be developed. In this study, the detailed structure-activity relationship of 1H-indazole analogues was studied. During this study, we found that the cell-free enzyme inhibitory potential of Rho kinase inhibitors having the 1H-indazole scaffold did not necessarily correlate with their inhibitory potential toward the chemotaxis of cultured cells. The choice of the linker substructure was shown to be an important factor for the 1H-indazole analogues to inhibit the chemotaxis of cells. Optimization of the 1H-indazole inhibitors with respect to the in vitro inhibition of monocyte chemotaxis induced by MCP-1 was carried out. The inhibitory potential was improved both in the cell-free enzyme assay and in the chemotaxis assay. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:350 / 364
页数:15
相关论文
共 23 条
[1]   The functional role of Rho and Rho-associated coiled-coil forming protein kinase in eotaxin signaling of eosinophils [J].
Adachi, T ;
Vita, R ;
Sannohe, S ;
Stafford, S ;
Alam, R ;
Kayaba, H ;
Chihara, J .
JOURNAL OF IMMUNOLOGY, 2001, 167 (08) :4609-4615
[2]  
FUKATA Y, 2001, TRENDS PHARMACOL SCI, P22
[3]   Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges [J].
Hu, E ;
Lee, D .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (04) :715-736
[4]  
IMAZAKI N, Patent No. 02100833
[5]   The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase [J].
Ishizaki, T ;
Maekawa, M ;
Fujisawa, K ;
Okawa, K ;
Iwamatsu, A ;
Fujita, A ;
Watanabe, N ;
Saito, Y ;
Kakizuka, A ;
Morii, N ;
Narumiya, S .
EMBO JOURNAL, 1996, 15 (08) :1885-1893
[6]  
Ishizaki T, 2000, MOL PHARMACOL, V57, P976
[7]   An essential part for Rho-associated kinase in the transcellular invasion of tumor cells [J].
Itoh, K ;
Yoshioka, K ;
Akedo, H ;
Uehata, M ;
Ishizaki, T ;
Narumiya, S .
NATURE MEDICINE, 1999, 5 (02) :221-225
[8]   Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina [J].
Masumoto, A ;
Mohri, M ;
Shimokawa, H ;
Urakami, L ;
Usui, M ;
Takeshita, A .
CIRCULATION, 2002, 105 (13) :1545-1547
[9]   Rho-associated kinase, a novel serine threonine kinase, as a putative target for the small GTP binding protein Rho [J].
Matsui, T ;
Amano, M ;
Yamamoto, T ;
Chihara, K ;
Nakafuku, M ;
Ito, M ;
Nakano, T ;
Okawa, K ;
Iwamatsu, A ;
Kaibuchi, K .
EMBO JOURNAL, 1996, 15 (09) :2208-2216
[10]   THE USE OF DIETHYL AZODICARBOXYLATE AND TRIPHENYLPHOSPHINE IN SYNTHESIS AND TRANSFORMATION OF NATURAL-PRODUCTS [J].
MITSUNOBU, O .
SYNTHESIS-STUTTGART, 1981, (01) :1-28